Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9325439 | Fertility and Sterility | 2005 | 4 Pages |
Abstract
The risk of placental transfer of rosiglitazone is much higher at or after 10 weeks of gestation. Absence of detectable rosiglitazone in amniotic fluid despite its presence in fetal tissue suggests that fetuses may have the ability to metabolize rosiglitazone, and little parent drug was excreted unchanged in urine.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Louis Yik-Si M.Med.Sc., John Hok-keung Ph.D., Tze Kin M.D.,